Edwards Lifesciences (EW) Cost of Revenue (2009 - 2026)

Edwards Lifesciences has reported Cost of Revenue for 18 years, with the latest figure at $392.4 million in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 13.94% year-over-year to $392.4 million in Q2 2026; TTM through Jun 2026 was $1.4 billion, a 20.16% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 19.39% from the prior year.
• Cost of Revenue was $392.4 million for Q2 2026 at Edwards Lifesciences, up from $362.6 million in the prior quarter.
• The five-year high for Cost of Revenue was $392.4 million in Q2 2026, with the low at -$98.8 million in Q4 2022.
• Average Cost of Revenue over 5 years is $278.8 million, with a median of $289.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue slumped 131.92% in 2022, then soared 354.05% in 2023.
• Over 5 years, Cost of Revenue stood at -$98.8 million in 2022, then surged by 354.05% to $251.0 million in 2023, then grew by 16.41% to $292.2 million in 2024, then grew by 17.39% to $343.0 million in 2025, then rose by 14.4% to $392.4 million in 2026.
• The last three Cost of Revenue figures came in at $392.4 million (Q2 2026), $362.6 million (Q1 2026), and $343.0 million (Q4 2025), per Business Quant data.